Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Brean Capital Sees 'Significant Uptake' for Progenics' (PGNX) Oral RelistorJuly 20, 2016 10:22 AM Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & CompanyJuly 20, 2016 9:16 AM Progenics Pharma (PGNX) Surges Over 20% as FDA Approval Oral RELISTORJuly 20, 2016 8:10 AM Rodman & Renshaw Reiterates Buy Rating on Valeant (VRX) July 20, 2016 8:02 AM BTIG Positive on Progenics Pharma (PGNX) Following FDA Approval of RELISTOR as OIC Treatment (VRX)July 20, 2016 7:57 AM Valeant (VRX) Pipeline Developments 'Positive', But In-Line with Expectations - BMO CapitalJuly 20, 2016 7:40 AM Valeant (VRX) FDA Catalysts a Mixed Bag and Expected, Now Focus on Earnings - Wells FargoJuly 20, 2016 6:52 AM Valeant (VRX) Oral Relistor Approval a 'Slight Positive' - RBC CapitalJuly 20, 2016 6:47 AM Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer PainJuly 19, 2016 6:04 PM